SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021.
The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.
CONTACT: Contacts: Investors Heather Rowe Armstrong VP, Investor Relations harmstrong@vir.bio +1-415-915-4228 Media Cara Miller VP, Corporate Communications cmiller@vir.bio +1-415-941-6746
New Digital Health Community Delivers Rare Disease Resources and Peer Support for ATTR Amyloidosis Patients…
Industry-leading health care firm closes 2025 with multiple Agency of the Year honors COLUMBUS, Ohio,…
ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a…
KENNEWICK, Wash. and HOUSTON, Dec. 11, 2025 /PRNewswire/ -- Cadwell, a global leader in neurodiagnostic…
New embedded solution empowers more than 900,000 small businesses to offer flexible, affordable health coverage directly…
CONSHOHOCKEN, Pa., Dec. 11, 2025 /PRNewswire/ -- Suvoda, a global clinical trial technology company, today announced…